Über uns

Scintomics Molecular, Applied Theranostics Technologies (ATT) is a growing player in the radiopharmaceutical business with a particular strategic emphasis on providing unrestricted supply and support of proprietary and innovative tracer technology and non-IP protected precursors, such as PSMA I&T (patent protected in several EU countries and Australia) and next generation PSMA inhibitors for radioligand therapy.

The well-known GRP Module Series became part of ATT in April when ATT took over the Module business from its Parent company Scintomics, which has been selling and installing fully automated production systems for established radio-pharmaceuticals in clinical facilities around the world since 2006.